Showing results (121-130 of 139) with videos related to
Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA TrialBenoit You, Patrick Robelin, Michel Tod, et al.JCO Precision Oncology|January 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO TrialFélix Blanc-Durand, Benoit You, Yahia Adnani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2019
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III StudyJulien Edeline, Meher Benabdelghani, Aurélie Bertaut, et al.Gastroenterology|June 19, 2012
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinomaRaphaël Maréchal, Jean-Baptiste Bachet, John R Mackey, et al.Oncotarget|December 20, 2017
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO studyJuliette Palle, David Tougeron, Astrid Pozet, et al.Molecular Cancer|August 13, 2024
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker researchAurélie Moniot, Christophe Schneider, Laure Chardin, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 10, 2022
Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instabilityClaire Boyer, David Sefrioui, Romain Cohen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC StudyThierry André, Armand de Gramont, Dewi Vernerey, et al.Gynecologic Oncology|October 26, 2021
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)Olivier Trédan, Magali Provansal, Cyril Abdeddaim, et al.JAMA Oncology|April 4, 2024
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical TrialDavid Tougeron, Laetitia Dahan, Ludovic Evesque, et al.Pageof 14